{"brief_title": "Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A", "brief_summary": "The purpose of this study is to determine the relative bioavailability of ReFacto AF as compared to ReFacto, when each is administered as 2-minute bolus infusions.", "condition": "Hemophilia A", "intervention_type": "Drug", "intervention_name": "ReFacto AF", "criteria": "Inclusion Criteria: - Severe hemophilia A (FVIII:C < 1% at local laboratory) - Previously treated patients (PTP) with at least 250 exposure days to any factor VIII product - Age greater than or equal to 12 years\\ Exclusion Criteria: - The presence of any bleeding disorder in addition to hemophilia A - Concomitant therapy with immunosuppressant drugs (e.g., intravenous immunoglobulin (IVIG), routine systemic corticosteroid use) - History of detectable factor VIII inhibitor", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038935.xml"}